Skip to main content
Premium Trial:

Request an Annual Quote

Predicine, Flagship Biosciences to Provide Combined Service

NEW YORK (GenomeWeb) – Predicine and Flagship Biosciences said Thursday that they have agreed to enter a strategic venture, which will combine Predicine's GeneRADAR molecular insights platform with Flagship's artificial intelligence-enabled cTA digital pathology platform for pharmaceutical customers in the immuno-oncology space.

The two companies said they will work together to provide an integrated molecular and contextual tissue biomarker solution. Predicine's GeneRADAR is a combined liquid biopsy assay for both circulating tumor DNA and circulating RNA targets. Flagship offers computational tissue imaging analysis for biomarker detection.

Predicine Founder and CEO Shidong Jia said in a statement that the partnership represents a furtherance of Predicine's goal to provide a comprehensive blood- and tissue-based biomarker profiling in support of global clinical trials. The company is based in Hayward, California.

The agreement also represents an expansion of Flagship's global footprint, with the Westminster, Colorado-based firm's technology now available through Predicine's CAP-accredited laboratories in China.

Financial and other terms of the deal were not disclosed.